Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13362540 | 0.74 | NOS3 (0.31) | — | |
| SCHEMBL21956967 | 0.72 | AR (0.35) | SORT1LRRK2 | |
| SCHEMBL21956733 | 0.72 | CFTR (0.45) | SORT1HPGDHSD17B10 | |
| SCHEMBL31027305 | 0.72 | CFTR (0.45) | SORT1HPGDHSD17B10 | |
| SCHEMBL31018120 | 0.72 | AR (0.35) | SORT1LRRK2 | |
| SCHEMBL24928213 | 0.72 | CYP1A2 (0.32) | CYP2C19CYP1A2 | |
| SCHEMBL12316308 | 0.71 | LMNA (0.33) | TRPA1 | |
| SCHEMBL22017363 | 0.71 | HPGD (0.34) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL24312083 | 0.71 | ALDH1A1 (0.38) | SORT1HPGDHSD17B10LRRK2 | |
| SCHEMBL23942638 | 0.71 | SORT1 (0.33) | SORT1HPGDHSD17B10TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11174256-B2 | Imidazopyridine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | SORT1 1623/4885CYP3A4 2052/4885CYP2D6 4014/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | SORT1 1256/4885CYP3A4 1745/4885CYP2D6 3490/4885 |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | SORT1 3767/4885CYP3A4 366/4885CYP2D6 251/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | SORT1 3767/4885CYP3A4 366/4885CYP2D6 251/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | SORT1 2649/4885CYP3A4 1019/4885CYP2D6 2941/4885 |
| US-11174256-B2 | Imidazopyridine derivatives | TPMT, IRAK4, CFTR | SORT1 4014/4885CYP3A4 48/4885CYP2D6 63/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | SORT1 3767/4885CYP3A4 366/4885CYP2D6 251/4885 |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | SORT1 4014/4885CYP3A4 48/4885CYP2D6 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.